{"name":"Elicio Therapeutics","slug":"elicio","ticker":"ELTX","exchange":"NASDAQ","domain":"elicio.com","description":"Elicio Therapeutics is a biopharmaceutical company focused on developing novel immunotherapies for the treatment of cancer. The company's pipeline includes several promising candidates, including ETX1154, a first-in-class, orally administered, small molecule immunomodulator. Elicio Therapeutics is positioned to capitalize on the growing demand for immunotherapy treatments in oncology. With a strong pipeline and experienced leadership team, Elicio Therapeutics is well-positioned for future growth.","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"Robert Connelly","sector":"Oncology / Immunotherapy","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$180M","metrics":{"revenue":2301000,"revenueGrowth":-91.9,"grossMargin":0,"rdSpend":24903000,"netIncome":-39571000,"cash":25862000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"ETX1154 patent cliff ($0.00 at risk)","drug":"ETX1154","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ELI-002 2P","genericName":"ELI-002 2P","slug":"eli-002-2p","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ELI-002 2P","genericName":"ELI-002 2P","slug":"eli-002-2p","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Elicio Therapeutics Announces FDA Clearance of IND for ETX9154","summary":"Elicio Therapeutics announced that the FDA has cleared the Investigational New Drug (IND) application for ETX9154, a novel immunotherapy candidate.","drugName":"ETX9154","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Elicio Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Elicio Therapeutics reported its third quarter 2023 financial results, highlighting progress in its pipeline and financial position.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE90SldBX2NuRmpucGJpeGxhb1JIbVAyZkx1MGtFZWNvUnlpRDA4TEtEVENUT3hqcDAxUFpiNTB5cGJlLWdLSjRRd3RlcGp2RWRmem9CTTdOQnh6ODBlV00zZ19xREd6R2JVQUtkQ3Bn?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Elicio Therapeutics, Inc. (ELTX) - Stock Titan","headline":"If You Invested $1,000 in Elicio Therapeutics, Inc. (ELTX)","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPR0Z4c1dka0FYS1R4eU9iQWVBdHlpSUN3RXZjVnhBY0FoZXhkX1ZNS0ZhMy1oZmNFTkhJUV80Tk4xTC1tRnVUZEhFX0NhNS1mVHpFQkt6MlVzRDdyNlpwd21XNTJFVDlfZVBWaUNwcms5V2c0TnNEY04zTW1CU3pnY3BrLVd2cjdqa2tqX1Rfa2tmdGNGMF94NXlnbnV1MmVrRTc4N1RKTlA3UTdzWkxzSU9PNVpLU21pSDBsVXJrRjFxclptSDJwckRrc195RUlwU1otNlQzX2xQckxFazduZUphSHRBUlnSAewBQVVfeXFMT2tJZm5kX0duYVE5dm8tZ2JnT0h1QkVNOG54OG0tUDZtdk4yQVpLcllBSDZEazB0aHM1VHpzbG1mWS0xYTdZTUlxUEh4RmI2QVplMXRRRHV4ZGg4MXF2dlp2OGNGb0RCeW9DOGh1VHJBd0U3RU0yOFVkYURkcEloTThkY3JUUVhZZ3ItdmFUU0dESW9uWW03Tmo5WGJFZFYtdnAzOWpsYWlPOGI0YXViUTR3NWxDV0xSWkFhQlpOeVBTTWhlajdlek9JSGg5YWNxaU9GTGwtZl96WWxNS2NYdF9lOXJqLU4wZHdGaE0?oc=5","date":"2026-02-10","type":"pipeline","source":"simplywall.st","summary":"Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt In A Risky Way? - simplywall.st","headline":"Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt In A Risky Way?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-20","type":"pipeline","source":"simplywall.st","summary":"Retail investors are Elicio Therapeutics, Inc.'s (NASDAQ:ELTX) biggest owners and were hit after market cap dropped US$8.5m - simplywall.st","headline":"Retail investors are Elicio Therapeutics, Inc.'s (NASDAQ:ELTX) biggest owners and were hit after market cap dropped US$8","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQUmt4T1BmOEhubUFzeHZIZEZkLWRhbmVEWl9sTkRKTzFmUzNMZmZtT1ptNkxHYjFLRE5FQXZKejAwNWIxQTRaNUpPb0oxNUtHUlkwUTAxZ1ItSVZBUW01M3N2SWt1ZTAwSUxJS2VEYlRaekE2VTlHZlZJazFoNDhPMmhYYTdvV0pyOVFsdVBMMjhZV3VMZGNuWTRvZzBNRGlGYnJjcW9TTWpkS005eFUyby13UUdMelpSTXlla0NBc3JIN2Z5WWM5ajNxOHFEOUJwUUF0dDBmYjJ0alFBSzJTMk1rV0Y5ek1xTlE?oc=5","date":"2025-11-19","type":"pipeline","source":"Elicio Therapeutics","summary":"Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer - Elicio Therapeutics","headline":"Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugJBVV95cUxQTEoxb25CaW9GTTF4N1JPNVNhb2RqODNtWkotQjVBTHExY1FZckFKMzFiZE9GQmhBN3Z5UkFJSWgzb2VIQnptN3hBWUt3bjU4TFpiTW5PVnBVSjB5UnN5SnNhVDM0MUo4b01QS1FYdUc0eURPNVpXYUdJZE9TdjZOUE1KRC15R0diX19WdzV2c3pRMjcyWEdvanNKVEtfMG1GTmUteUFEcmE0a2JLTWwzUXVwRllwb3dHNWdSdWVSbWV2ZlR5MS1sb0FUNE5uZjVnNFpvRDRMRV81QXFxZTRiMWxqdjRIRE42V0tBWTM5aWhvNm5RTzdiSHVyc045NjJmVmlCNFRYcm9QaDFUZ01TZm9YYWxETWlpU1d2dDE1eWVWbzVsamRYLVR6VVUxbVNfWnpjMGc2X0RXZw?oc=5","date":"2025-08-12","type":"trial","source":"Elicio Therapeutics","summary":"Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients - Elicio Thera","headline":"Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for M","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFBXTWYySEVpNFhjSFdPZDNOa3VOMzJfMk5tTEZ3cmhvckFmN0JxeVJ6dXA1MWljakVUMVJybG9zU3ZkMGVUTEt2NzZpN2JWWnh1Y2c?oc=5","date":"2024-06-27","type":"pipeline","source":"Yahoo Finance Australia","summary":"Elicio Therapeutics, Inc. (ELTX) stock price, news, quote and history - Yahoo Finance Australia","headline":"Elicio Therapeutics, Inc. (ELTX) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBnNzBiNG4tTHhIcVZaalJCOGtKMUNFMF8yMWpmSHdnUkpMRmpTMFZNeTlLeEVMQTlGajc3UndMblBOTzRZSHVENWdrVkhReEVs?oc=5","date":"2024-01-09","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPenlfMFp2d3A3ajZTVjhlcjdoVERQLVhqNEx1STF4M3B2MUJsVXRPV3lvTkFWRUtseF83Z2JUc1hWellFc1pPVXlLSUdJZlFvZHFhMWFKRzBSeWpjOUt3SnZKNDU0YzlJZVV4U2tPc0gtTXJCQnJIYWZWNUZjWEg3RElfWlpvSHhnQXY2TDBPTHd3MmRJZkhTMWhqaVVKSzZ5NWJGNGVHcUZTS1k?oc=5","date":"2023-06-01","type":"deal","source":"Elicio Therapeutics","summary":"Elicio Therapeutics Announces Completion of Merger with Angion Biomedica - Elicio Therapeutics","headline":"Elicio Therapeutics Announces Completion of Merger with Angion Biomedica","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNUFBFamt6ZWdNLTFfU0l6VFZJZHdXLW1mR01ta0gxQlFNUmhnT2hFNlp6ZVRYR2hva21hRmxXcjlGcXRCX3RMVjRvUWdpOW1fNUlNd2U1b0w5Y09HSmNfN1ktcGNCWDhkVTZvTHVaZUFEVkhOUTdFSmJZazlmYzhrbkxoVkh4bjNHRVdwdERwMGRSWmhfNUJz?oc=5","date":"2023-01-17","type":"deal","source":"BioPharma Dive","summary":"With reverse merger, Elicio becomes latest biotech to bypass an IPO - BioPharma Dive","headline":"With reverse merger, Elicio becomes latest biotech to bypass an IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE1yNDVzRC0yZDh1eUszRXZoRng4UW1hai14MTZmSFo4MTVtZkxMM3dYUU5xWjRld2hJLWNDTXpkNW4weVlLdzdtN1AyNTN2MVJDenc?oc=5","date":"2021-07-25","type":"pipeline","source":"Yahoo Finance UK","summary":"Elicio Therapeutics, Inc. (ELTX) stock price, news, quote and history - Yahoo Finance UK","headline":"Elicio Therapeutics, Inc. (ELTX) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"ETX1154","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Pfizer Inc."],"therapeuticFocus":["Oncology","Immunotherapy"],"financials":{"source":"sec_edgar","revenue":2301000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":2301000,"period":"2022-12-31"},{"value":28312000,"period":"2021-12-31"},{"value":28312000,"period":"2021-12-31"},{"value":2880000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":24903000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-39571000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":25862000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}